
NovoCure Limited: updates and filings
Price
$10.71
November 20, 2026Market cap $1.2B
What Ploutos Investor adds for NovoCure
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Oct 29, 2026next Jan 29, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
October 2026
July 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 9, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 9, 2026Regulation FD disclosureForm8-K
- Oct 29, 2026Shares registered for employeesFormS-8
- Oct 29, 2026Results of operationsForm8-K
- Oct 29, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 1, 2026Regulation FD disclosureForm8-K
- Sep 9, 2026Officer or director changeForm8-K
- Sep 1, 2026Other material eventsForm8-K
- Jul 23, 2026Results of operationsForm8-K
- Jul 23, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Jun 30, 2026Regulation FD disclosureForm8-K
- Jun 18, 2026Regulation FD disclosureForm8-K
- Jun 5, 2026Officer or director change, shareholder voteForm8-K
- May 21, 2026Additional annual meeting materialFormDEFA14A
- May 8, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 30, 2026Results of operationsForm8-K
- Apr 30, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 24, 2026Officer or director change (amendment)Form8-K/A
- Apr 20, 2026Additional annual meeting materialFormDEFA14A
- Apr 20, 2026Annual meeting proxy statementFormDEF 14A
- Apr 9, 2026Officer or director changeForm8-K
- Mar 26, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Mar 26, 2026Regulation FD disclosureForm8-K
- Feb 26, 2026Shares registered for employeesFormS-8
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 9, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 9, 2026 | 8-K | Regulation FD disclosure | Document |
| Oct 29, 2026 | S-8 | Shares registered for employees | Document |
| Oct 29, 2026 | 8-K | Results of operations | Document |
| Oct 29, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 1, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 9, 2026 | 8-K | Officer or director change | Document |
| Sep 1, 2026 | 8-K | Other material events | Document |
| Jul 23, 2026 | 8-K | Results of operations | Document |
| Jul 23, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Jun 30, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 18, 2026 | 8-K | Regulation FD disclosure | Document |
| Jun 5, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 21, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 8, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 30, 2026 | 8-K | Results of operations | Document |
| Apr 30, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 24, 2026 | 8-K/A | Officer or director change (amendment) | Document |
| Apr 20, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 20, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 9, 2026 | 8-K | Officer or director change | Document |
| Mar 26, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Mar 26, 2026 | 8-K | Regulation FD disclosure | Document |
| Feb 26, 2026 | S-8 | Shares registered for employees | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 24, 2015.
The full analysis
What do NovoCure's filings show?
The filings are where every one of NovoCure's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.